Product Information
SUCRALFATE 1 GM/10 ML SUSP is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1241 per ML under NDC 00378920535. Its NADAC has been published 204 times since Nov 9, 2022.
FDA first approved this application on Sep 12, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 g/10mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378920535
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUCRALFATEApproval Type
Generic (ANDA)
FDA Application
ANDA212913FDA Approved
9/12/2022
TE Code
AB
On Market Since
9/22/2022
Pharmacological Classes
Price Statistics
The NADAC for SUCRALFATE 1 GM/10 ML SUSP has been published 204 times since Nov 9, 2022, and over the history we have for it it has declined 61.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1241 per ML |
|---|---|
| All-time high | $0.3838 (Oct 11, 2023) |
| All-time low | $0.1153 (Jul 22, 2026) |
| 52-week high | $0.1253 |
| 52-week low | $0.1153 |
| Median price | $0.2304 |
| Average price | $0.2297 |
| Largest weekly change | +53.6% (Jun 19, 2024) |
| Weeks tracked | 204 |
| Tracking since | Nov 9, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the sucralfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sucralfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aluminum Complex class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUCRALFATE 1 GM/10 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for SUCRALFATE 1 GM/10 ML SUSP, manufactured by Mylan Pharmaceuticals Inc., is $0.1241 per ML (NDC 00378920535), effective Sep 30, 2026.
How has the price of SUCRALFATE 1 GM/10 ML SUSP changed over time?
Over the history we have for it, the NADAC for SUCRALFATE 1 GM/10 ML SUSP has declined 61.5%. It has been tracked across 204 weekly CMS publications since Nov 9, 2022.
What are the highest and lowest recorded NADAC prices for SUCRALFATE 1 GM/10 ML SUSP?
Since Nov 9, 2022, the NADAC for SUCRALFATE 1 GM/10 ML SUSP has ranged from a low of $0.1153 (Jul 22, 2026) to a high of $0.3838 (Oct 11, 2023), with a median of $0.2304 per ML.
Are there cheaper alternatives to SUCRALFATE 1 GM/10 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of SUCRALFATE 1 GM/10 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SUCRALFATE 1 GM/10 ML SUSP?
SUCRALFATE 1 GM/10 ML SUSP (NDC 00378920535) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.